PER-086-11未知未知
A BLINDED EXTENSION TO 5 YEARS OF A PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF ODANACATIB (MK-0822) TO REDUCE THE RISK OF FRACTURE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN TREATED WITH VITAMIN D AND CALCIUM
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2011年12月2日最近更新:
试验速览
- 阶段
- 未知
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65 至 99（—）
- 性别
- Female
入选标准
- •1) PATIENT COMPLETED THE BASE STUDY ON BLINDED STUDY THERAPY PNO18 (NOTE THAT AN INTERRUPTION UP TO 6 WEEKS AT END OF THE BASE STUDY IS ACCEPTABLE).
- •2) PATIENT HAS AT LEAST ONE HIP (eg., CONTAINS NO ELEMENTS FROM ORTHOPEDIC PROCEDURES) AND SUITABLE SPINAL ANATOMY THAT IS EVALUABLE BY DXA.
- •3) PATIENT UNDERSTANDS THE STUDY PROCEDURES, ALTERNATIVE TREATMENTS AVAILABLE, AND RISK INVOLVED WITH THE STUDY, AND VOLUNTARILY AGREES TO PARTICIPATE BY PROVIDING INFORMED CONSENT.
- •4) PATIENT SUBJECT IS ABLE TO READ, UNDERSTAND AND COMPLETE QUESTIONNAIRES AND DIARIES.
- •NOTE: IF A PATIENT WHO UNDERSTANDS THE PURPOSE AND USE OF THE DIARY CARDS AND STUDY QUESTIONNAIRE IS UNABLE TO COMPLETE THESE WITHOUT ASSISTANCE (eg., to VISUAL PROBLEMS, DIFFICULTY WRITING DUE TO ARTHRITIS, INABILITY TO READ, ETC.) A FAMILY MEMBER OR CARE-GIVER MAY ASSIST OF MAY COMPLETE THE DIARY CARD ON HER BEHALF.
排除标准
- •1) PATIENT HAS A HISTORY OR CURRENT EVIDENCE OF ANY CONDITION, THERAPY. LAB ABNORMALITY OF OTHER CIRCUNSTANCE THAT MUGHT CONFOUND THE RESULTS OF THE STUDY, OR INTERFERE WITH THE PATIENT´S PARTICIPATION FOR THE FULL DURATION OF THE STUDY, SUCH THAT IT IS NOT IN THE BEST INTEREST OF THE PATIENT TO PARTICIPATE.
- •2) PATIENT MET EXCESSIVE BONE LOSS CRITERIA AS DEFINED IN THE BASE STUDY.
- •3) PATIENT MET ANY OF DISCONTINUATION RULES AS DEFINED IN THE BASE STUDY PNO18.
- •4) PATIENT IS RECEIVING TREATMENT WITH:
- •A. CURRENT USE OF OSTEOPOROSIS THERAPY INCLUDING: BISPHOSPHONATES, PTH, STRONTIUM, SYSTEMIC ESTROGEN ± PROGESTIN, RALOXIFENE OR OTHER SERM, RANK LIGAND INHIBITOR, OR SUB-CUTANEOUS CALCITONIN. (NOTE: USE OF INTRANASAL CALCITONIN IS PERMITTED).
- •B. CURRENT USE OF LONG-TERM THERAPY (6 MONTHS) WITH ANY STRONG CYP3A4 INDUCERS (eg., RIFAMPIN, PHENOBARBITAL, BARBITURATES, CARBAMAZEPINE, PHENYTOIN, ST. JOHN´S, WORT, NEVIRAPINE, EFAVIRENZ, ETRAVIRINE).
- •C. CURRENT USE OF SYSTEMATICALLY ADMINISTERED AZOLE ANTIFUNGALS (eg., KETOCONAZOLE, FLUCONAZOLE, ITRACONAZOLE, MICONAZOLE, POSACONOZOLE, RAVUCONAZOLE AND VORICONAZOLE) BECAUSE OF THEIR STRONG INHIBITORY EFFECT ON CYP3A4.
研究者
相似试验
进行中（未招募）
1 期
A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumMedDRA version: 14.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2007-002693-66-GBMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co.16,071
进行中（未招募）
1 期
Extension to the Odanacatib Fracture Trial (PN018)MedDRA version: 17.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersosteoporosisEUCTR2014-002587-33-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.16,071
进行中（未招募）
1 期
An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumMedDRA version: 17.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2007-002693-66-EEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.8,254
进行中（未招募）
1 期
An Open-Label 5-Year 2nd Extension for 5 years to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumMedDRA version: 19.0 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2007-002693-66-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A.16,071
进行中（未招募）
1 期
A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumPostmenopausal OsteoporosisEUCTR2011-005514-10-LTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.8,254